Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary Guangzhou Apichope Pharmaceutical Co., Ltd. has received acceptance from the National Medical Products Administration for the clinical trial application of its self-developed innovative drug APH03621 tablet, and has received the "Acceptance Notice."
APH03621 is a novel oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist (GnRH-ant) developed by the company, intended for the treatment of endometriosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.